High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas

被引:120
|
作者
Haas, RLM
Poortmans, P
de Jong, D
Aleman, BMP
Dewit, LGH
Verheij, M
Hart, AAM
van Oers, MHJ
van der Hulst, M
Baars, JW
Bartelink, H
机构
[1] Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands
[4] Bernard Verbeeten Inst, Dept Radiotherapy, Tilburg, Netherlands
[5] Acad Med Hosp, Dept Haematol, Amsterdam, Netherlands
关键词
D O I
10.1200/JCO.2003.09.542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma. Patients and Methods: A total of 109 assessable patients (304 symptomatic sites) were irradiated (53 males and 56 females; median age, 62 years; range, 35 to 93), including 98 patients with follicular lymphoma (43 grade 1 and 55 grade 2), nine extranodal marginal zone lymphomas of mucoso-associated lymphoid tissue-type and two patients with lymphoplasmacytoid lymphoma. Bulky disease (greater than or equal to5 cm) was present in 52% of all patients. A median of two prior regimens (range, 0 to 11) preceded LD-IF-RT. The median time since diagnosis was 41 months (range, 2 to 358 months) Time to (local) progression was calculated according to the Kaplan-Meier method. Differences in response rates between treatments within the some patient were compared using the McNemar test. Results: The overall response rate was 92%; complete response was reached in 67 patients (61%), partial response in 34 patients (31%), stable disease in six patients (6%), and progressive disease in two patients (2%). The median time to progression was 14 months. The median time to local progression was 25 months. The 67 patients with complete response showed a median time to progression of 25 months and a median time to local progression of 42 months. None of the factors studied (age, sex, follicular lymphoma grade, radiotherapy regimen, number of previous regimens and previous history, number of positive sites or largest lymphoma diameter) were found to be related to response rate. Conclusion: LD-IF-RT is a valuable asset in. the management of patients with follicular lymphoma and should be considered in patients with recurrent disease. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:2474 / 2480
页数:7
相关论文
共 50 条
  • [31] Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery
    Kushner, BH
    Wolden, S
    LaQuaglia, MP
    Kramer, K
    Verbel, D
    Heller, G
    Cheung, NKV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2821 - 2828
  • [32] Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study
    Goyal, Amrita
    Carter, Joi B.
    Pashtan, Itai
    Gallotto, Sara
    Wang, Irene
    Isom, Scott
    Ng, Andrea
    Winkfield, Karen M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (02) : 408 - 410
  • [33] Low-dose radiotherapy (4 Gy) in the treatment of marginal zone B- cell lymphomas
    Cerrato, M.
    Orlandi, E.
    Vella, A.
    Bartoncini, S.
    Iorio, G. C.
    Bongiovanni, D.
    Capriotti, F.
    Boccomini, C.
    Vassallo, F.
    Cavallin, C.
    De Luca, V.
    Giglioli, F. R.
    Ricardi, U.
    Levis, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S898 - S899
  • [34] Local Progression after Low-dose Involved-field Radiation for Non-Hodgkin Lymphoma
    Martin, N. E.
    Ng, A. K.
    Luthy, S. K.
    Webber, B. T.
    Freedman, A. S.
    Mauch, P. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S481 - S481
  • [35] EFFICACY AND TOXICITY OF MULTIAGENT CHEMOTHERAPY AND LOW-DOSE INVOLVED-FIELD RADIOTHERAPY IN CHILDREN AND ADOLESCENTS WITH HODGKINS-DISEASE
    HUDSON, MM
    GREENWALD, C
    THOMPSON, E
    WILIMAS, J
    MARINA, N
    FAIRCLOUGH, D
    KAUFFMAN, W
    BOZEMAN, P
    MACKERT, PW
    ABROMOWITCH, M
    JENKINS, J
    BOULDEN, T
    KUN, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 100 - 108
  • [36] Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma
    Vassilakopoulos, TP
    Angelopoulou, MK
    Siakantaris, MP
    Kontopidou, FN
    Dimopoulou, MN
    Kokoris, SI
    Kyrtsonis, MC
    Tsaftaridis, P
    Karkantaris, C
    Anargyrou, K
    Boutsis, DE
    Variamis, E
    Michalopoulos, T
    Boussiotis, VA
    Panayiotidis, P
    Papavassiliou, C
    Pangalis, GA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (03): : 765 - 781
  • [37] High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
    Karl Bremer
    [J]. Journal of Cancer Research and Clinical Oncology, 2002, 128 : 603 - 609
  • [38] High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
    Bremer, K
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) : 603 - 609
  • [39] Low-dose radiotherapy effects the progression of anti-tumor response
    Gao, Lei
    Zhang, Anqi
    [J]. TRANSLATIONAL ONCOLOGY, 2023, 35
  • [40] KINETICS OF INTERACTION OF HYPERTHERMIA AND RADIATION AT HIGH AND LOW-DOSE RATES
    SZECHTER, A
    KOWALSKY, WP
    SCHWARZ, G
    [J]. RADIATION RESEARCH, 1981, 87 (02) : 413 - 413